Beckman Coulter’s Bruce Wallace is one of the few executives in the molecular biology tools industry whose job responsibilities and job title specifically address the emerging systems-biology market.

Wallace, 54, is vice president and director of Beckman’s systems biology business center, a post he has held for one year after joining the Fullerton, Calif., company three years ago from Nanogen, where he was vice president for research and development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.